Moderna, Inc.
(MRNA)CIK 1682852 · SEC filings only
harness minimum not met
Not enough resolved promises to grade
3 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.
Resolved promises
Full say-do history
Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.
See Pro →Credibility timeline
Timeline as a list
- Nov 3, 2023KEPTThe Board of Directors has authorized a share repurchase program of up to $1 billion over a two-year period
- Feb 23, 2024KEPTThe Board of Directors has authorized a share repurchase program of up to $1 billion
- May 2, 2024KEPTThe Board of Directors has authorized a new share repurchase program for $3 billion
harness minimum not met
Sector median (Life Sciences): B across 7 graded companies
Not enough comparable guidance to grade
1 of the 4 resolved guidance promises needed to publish a reliability grade. Some of this company’s guidance has no reported figure we can compare it with. It is shown below, never scored; the line under each statement says why. Here's what we're tracking — we never show a grade we can't back with receipts.
Resolved promises
Full say-do history
Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.
See Pro →Guidance by basis
0 of 1 guidance figures that were graded or dropped for basis could not be graded on the same basis (0%). Guidance marked “not judged” is in neither number.
| Guidance type | Said | Graded | Dropped | Other |
|---|---|---|---|---|
| Revenue · basis not stated | 2 | 1 | 0 | 1 |
Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.
Guidance shown, not graded (1)
We show what was said — with its source filing — but never score it. The line under each statement says why.
- revenue guidance fy · Nov 4, 2021Expected to realize product sales for FY 2021 between $15 billion and $18 billion.Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
Credibility timeline
Timeline as a list
- Feb 24, 2023IN LINEthe Company believes 2022 sales could be in the range of $17 billion to $22 billion.